An intravenous monoclonal antibody to the interleukin-6 receptor, proposed for the second- or third-line treatment of children with juvenile idiopathic arthritis.
If you have a Hayes login, click here to view the full report on the Knowledge Center.
An intravenous monoclonal antibody to the interleukin-6 receptor, proposed for the second- or third-line treatment of children with juvenile idiopathic arthritis.
If you have a Hayes login, click here to view the full report on the Knowledge Center.